Have a feature idea you'd love to see implemented?
Let us know!
IMVT Immunovant Inc
Price (delayed)
$30
Market cap
$4.39B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.93
Enterprise value
$3.83B
Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. Immunovant is developing IMVT-1401, a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous
Highlights
Immunovant's debt has shrunk by 92% YoY and by 50% QoQ
IMVT's quick ratio has surged by 94% year-on-year but it is down by 5% since the previous quarter
The equity has soared by 82% YoY but it has contracted by 12% from the previous quarter
IMVT's net income is down by 11% YoY and by 5% from the previous quarter
Immunovant's EPS has decreased by 2.7% QoQ
Key stats
What are the main financial stats of IMVT
Market
Valuations
Earnings
Shares outstanding
146.37M
Market cap
$4.39B
Enterprise value
$3.83B
Price to earnings (P/E)
N/A
Price to book (P/B)
8.04
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$271.89M
EBITDA
-$270.73M
Free cash flow
-$243.55M
Per share
Balance sheet
Liquidity
EPS
-$1.93
Free cash flow per share
-$1.67
Book value per share
$3.73
Revenue per share
$0
TBVPS
$4.04
Total assets
$589.68M
Total liabilities
$45.02M
Debt
$69,000
Equity
$544.66M
Working capital
$544.03M
Debt to equity
0
Current ratio
13.08
Quick ratio
12.49
Net debt/EBITDA
2.07
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-48.2%
Return on equity
-52.1%
Return on invested capital
N/A
Return on capital employed
-49.9%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
IMVT stock price
How has the Immunovant stock price performed over time
Intraday
1.35%
1 week
2.85%
1 month
5.86%
1 year
-11.24%
YTD
-28.79%
QTD
5.23%
Financial performance
How have Immunovant's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$298.51M
Net income
-$272.55M
Gross margin
N/A
Net margin
N/A
The operating income has declined by 16% year-on-year and by 6% since the previous quarter
IMVT's net income is down by 11% YoY and by 5% from the previous quarter
Growth
What is Immunovant's growth rate over time
Valuation
What is Immunovant stock price valuation
P/E
N/A
P/B
8.04
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Immunovant's EPS has decreased by 2.7% QoQ
The equity has soared by 82% YoY but it has contracted by 12% from the previous quarter
The stock's price to book (P/B) is 32% more than its 5-year quarterly average of 6.0 but 27% less than its last 4 quarters average of 10.9
Efficiency
How efficient is Immunovant business performance
IMVT's return on equity is up by 22% year-on-year and by 7% since the previous quarter
IMVT's return on assets is up by 19% year-on-year and by 6% since the previous quarter
Dividends
What is IMVT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for IMVT.
Financial health
How did Immunovant financials performed over time
IMVT's quick ratio has surged by 94% year-on-year but it is down by 5% since the previous quarter
Immunovant's current ratio has surged by 92% YoY but it has decreased by 4.5% QoQ
Immunovant's debt is 100% lower than its equity
Immunovant's debt has shrunk by 92% YoY and by 50% QoQ
The equity has soared by 82% YoY but it has contracted by 12% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.